168 related articles for article (PubMed ID: 19260121)
41. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
42. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
43. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
44. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
45. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Jabbour E; Kantarjian HM; Jones D; Reddy N; O'Brien S; Garcia-Manero G; Burger J; Cortes J
Blood; 2008 Dec; 112(13):4839-42. PubMed ID: 18818391
[TBL] [Abstract][Full Text] [Related]
46. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
47. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Khorashad JS; Milojkovic D; Mehta P; Anand M; Ghorashian S; Reid AG; De Melo V; Babb A; de Lavallade H; Olavarria E; Marin D; Goldman JM; Apperley JF; Kaeda JS
Blood; 2008 Feb; 111(4):2378-81. PubMed ID: 17982022
[TBL] [Abstract][Full Text] [Related]
48. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Grant H; Jiang X; Stebbing J; Foroni L; Craddock C; Griffiths M; Clark RE; O'Brien S; Khorashad JS; Gerrard G; Wang L; Irving JA; Wang M; Karran L; Dyer MJ; Forrest D; Page K; Eaves CJ; Woolfson A
Leukemia; 2010 Oct; 24(10):1817-21. PubMed ID: 20739956
[No Abstract] [Full Text] [Related]
49. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
O'Hare T; Eide CA; Deininger MW
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S120-30. PubMed ID: 17382021
[TBL] [Abstract][Full Text] [Related]
50. Targeted CML therapy: controlling drug resistance, seeking cure.
O'Hare T; Corbin AS; Druker BJ
Curr Opin Genet Dev; 2006 Feb; 16(1):92-9. PubMed ID: 16343892
[TBL] [Abstract][Full Text] [Related]
51. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford S; Melo JV; Hughes TP
Blood; 2009 Dec; 114(27):5426-35. PubMed ID: 19880502
[TBL] [Abstract][Full Text] [Related]
52. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.
Nieborowska-Skorska M; Flis S; Skorski T
Leukemia; 2014 Dec; 28(12):2416-8. PubMed ID: 25151958
[No Abstract] [Full Text] [Related]
53. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
54. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
O'Hare T; Eide CA; Deininger MW
Blood; 2007 Oct; 110(7):2242-9. PubMed ID: 17496200
[TBL] [Abstract][Full Text] [Related]
55. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
56. A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
Kuang P; Liu T; Huang Q; Ye Y; Xiang B; Huang J; Diwu L; Wang Y; Meng W; Dong T; Yang S; Lu X
Leuk Res; 2012 Aug; 36(8):e159-62. PubMed ID: 22578778
[No Abstract] [Full Text] [Related]
57. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
Li YF; Liu X; Liu DS; Din BH; Zhu JB
Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
[No Abstract] [Full Text] [Related]
58. Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
La Rosée P; Hochhaus A
Curr Hematol Malig Rep; 2008 Apr; 3(2):72-9. PubMed ID: 20425450
[TBL] [Abstract][Full Text] [Related]
59. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
[TBL] [Abstract][Full Text] [Related]
60. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]